Shanghai, 3Sbio Inc. announced that China's first Glucagon-like peptide-1 (GLP-1) receptor agonist weekly preparation Bydureon (generic name Exenatide Microsphere for injection) has been formally approved by China Food and Drug Administration (CFDA), as a new treatment option to improve glycemic control for patients with type 2 diabetes. At present, the GLP-1 receptor agonist weekly preparation has been launched in markets such as the United States, Europe, Japan, South Korea, Hong Kong and Taiwan, and has good safety as demonstrated in the clinical experience for patients with type 2 diabetes.